---
title: "Sector Update: Healthcare Stocks Gain in Afternoon Trading"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286140558.md"
description: "Healthcare stocks experienced gains on May 12, 2026, with the NYSE Healthcare Index up 2.1% and the State Street Healthcare Select Sector SPDR ETF rising 2.2%. Alkermes saw a 5% increase after positive trial results for its Lumryz oral suspension. RBC Capital Markets upgraded Sonida Senior Living's price target to $45, noting its strong Q1 results, leading to a 1.5% rise in shares. Agios Pharmaceuticals rose 1% after submitting a New Drug Application for mitapivat to treat sickle cell disease."
datetime: "2026-05-12T17:54:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286140558.md)
  - [en](https://longbridge.com/en/news/286140558.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286140558.md)
---

# Sector Update: Healthcare Stocks Gain in Afternoon Trading

01:54 PM EDT, 05/12/2026 (MT Newswires) -- Healthcare stocks rose Tuesday afternoon, with the NYSE Healthcare Index adding 2.1% and the State Street Healthcare Select Sector SPDR ETF (XLV) climbing 2.2%.

The iShares Biotechnology ETF (IBB) increased 1.4%.

In corporate news, Alkermes ( ALKS ) shares jumped past 5% after it said Tuesday a late-stage trial evaluating its investigational Lumryz oral suspension in adults with idiopathic hypersomnia, a rare condition in which patients require excessive sleep, met all primary and key secondary endpoints.

Sonida Senior Living's ( SNDA ) recent stock decline was unwarranted given the broad-based strength in its Q1 results, RBC Capital Markets said in a note. RBC reiterated its outperform rating on the stock and raised its price target to $45 per share from $39. Sonida shares added 1.5%.

Agios Pharmaceuticals ( AGIO ) shares rose 1% after it said Tuesday it has submitted a supplemental New Drug Application to the US Food and Drug Administration seeking accelerated approval of mitapivat for the treatment of sickle cell disease.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

### Related Stocks

- [AGIO.US](https://longbridge.com/en/quote/AGIO.US.md)
- [ALKS.US](https://longbridge.com/en/quote/ALKS.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [SNDA.US](https://longbridge.com/en/quote/SNDA.US.md)
- [RY.US](https://longbridge.com/en/quote/RY.US.md)

## Related News & Research

- [Agios Pharmaceuticals Touts Strong AQVESME Launch as Sickle Cell Filing Advances](https://longbridge.com/en/news/286947828.md)
- [Wells Fargo Sticks to Its Buy Rating for Alkermes (ALKS)](https://longbridge.com/en/news/286252932.md)
- [UnitedHealth Group Incorporated $UNH Holdings Boosted by GSA Capital Partners LLP](https://longbridge.com/en/news/286878927.md)
- [Virtuix Expands Into AI-Assisted Neurodivergent Therapy Through Rutgers University Collaboration | VTIX Stock News](https://longbridge.com/en/news/287075316.md)
- [Airbnb director Joseph Gebbia disposes of USD 7.23 million Class A shares](https://longbridge.com/en/news/287119131.md)